Regulations.gov document
Reference 8 - Screening Clinical Cell Products for Replication Competent Retrovirus The…
Supporting & Related Material · FDA-2018-D-2173 · posted Mar 6, 2020
Key facts
| Document ID | FDA-2018-D-2173-0072 |
|---|---|
| Title | Reference 8 - Screening Clinical Cell Products for Replication Competent Retrovirus The National Vector Bioreository Experience re Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2018-D-2173 |
| Posted | Mar 6, 2020 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: